National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Atezolizumab (Tecentriq®) for triple-negative breast cancer.

Atezolizumab in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.


NCPE Assessment Process Complete
Rapid review commissioned 03/07/2019
Rapid review completed 19/07/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 30/07/2019
Pre-submission consultation with Applicant 07/10/2019
Initial submission received from Applicant 09/12/2019
Complete submission received from Applicant 13/01/2020
Preliminary review sent to Applicant 05/05/2020
NCPE assessment re-commenced 29/05/2020
Factual accuracy check sent to Applicant 06/08/2020
NCPE assessment re-commenced 14/08/2020
NCPE assessment completed 01/09/2020
NCPE assessment outcome The NCPE recommends that atezolizumab (Tecentriq®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.


The HSE has approved reimbursement following confidential price negotiations March 2022.